ArticleCancer management and research2026
Clinical Research on Integrated Chinese and Western Medicine for Colorectal Cancer with Lung Metastases.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of integrated traditional Chinese and Western medicine (TCM-WM) treatment on survival outcomes in patients with colorectal cancer (CRC) lung metastases. Methods: A retrospective cohort study was conducted utilizing medical records of patients diagnosed with CRC lung metastases from four tertiary Grade A hospitals between August 2013 and December 2022. Patients were stratified based on exposure to continuous traditional Chinese medicine treatment for ≥3 months. Patients meeting this exposure criterion were assigned to the TCM-WM cohort; those not meeting the criterion were assigned to the Western medicine (WM) cohort. Overall survival (OS) and 3-, 4-, and 5-year cumulative survival rates were compared between cohorts. Results: The study included 286 patients with CRC lung metastases: 122 in the TCM-WM cohort and 164 in the WM cohort. Median OS was 35.0 months in the TCM-WM cohort versus 28.5 months in the WM cohort, representing a statistically significant extension of 6.5 months [HR= 0.67, 95% CI:0.514-0.871, Conclusion: Integrated TCM-WM treatment significantly prolongs survival and reduces mortality risk in patients with CRC lung metastases. (Trial registration No. ITMCTR2025001663).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.